Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 ...

SAN DIEGO, CA, USA I April 17, 2025 I Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted ...

Collaboration combines BigHat's AL/ML-powered Milliner™ platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.

GENEVA, Switzerland I April 17, 2025 I Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...